Home

Enlivex Therapeutics Ltd. (ENLV)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Enlivex Therapeutics Ltd. (ENLV)

Go deeper and ask any question about ENLV

Company Performance

Current Price

as of Sep 13, 2024

$1.57

P/E Ratio

N/A

Market Cap

$33.61M

Description

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Metrics

Overview

  • HQNess Ziona, TA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerENLV
  • Price$1.57-1.26%

Trading Information

  • Market Cap$33.61M
  • Float87.30%
  • Average Daily Volume (1m)86,675
  • Average Daily Volume (3m)64,597
  • EPS-$1.19

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$3.10M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$2.83M
  • EV$2.53M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
Documents